This case study goes into how a global biopharmaceutical company became a leader in ethical AI. Faced with the challenge of preparing for future AI regulations, the company developed a comprehensive AI governance framework to ensure responsible AI practices. The EY team used its global Responsible AI framework to review and enhance the company's AI governance, addressing risks throughout AI's lifecycle. Although the audit identified gaps, it led to the establishment of minimum AI requirements. This proactive approach positions the biopharma at the forefront of ethical AI, ready for impending global AI regulations and dedicated to maintaining innovation without compromising values. Read the full study here.
Back to the overview
Share
Sector news
20-12-2023